Dapagliflozin approved for heart failure across LVEFs
European Pharmaceutical Review
DECEMBER 12, 2022
The approval means potentially a further 250,000 patients across the full spectrum of LVEF >40 percent, including HF with reduced, mildly reduced, and preserved ejection fraction (HFrEF, HFmrEF, HFpEF) will be eligible for treatment in England and Wales. percent of patients (n=1361) in the dapagliflozin group and in 45.5
100 
Let's personalize your content